fashion -WSS

fashion

author：fashion 2025-09-30 21:22:21 - browse：536

Adam's take main illustration — Molly Ferguson/STAT

This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study.

A looming test for neoantigen cancer vaccines

Before the end of the quarter, Gritstone Bio will release preliminary results from a randomized, Phase 2 clinical trial investigating a personalized therapeutic cancer vaccine in microsatellite-stable colon cancer, a type of “immunologically cold” tumor that is resistant to immunotherapies like PD-1/PD-L1 inhibitors.

The Gritstone vaccine is designed to train a patient’s own T cells to recognize and kill cancer cells by targeting mutated cancer proteins, called neoantigens, that are unique to a patient’s own tumor. It’s a relatively new approach for cancer vaccines — made possible by powerful and relatively inexpensive genomic sequencing of tumors – that is intended to overcome all the previous failures in the field. Gritstone’s effort is also similar to one being used by Moderna and Merck that has reported encouraging results in melanoma — and is now being investigated in a Phase 3 study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： BridgeBio heart drug succeeds in pivotal study

WSS

Gene therapy for Afghan refugees’ infant will be fully covered

House passes resolution saying Israel isn't a 'racist or apartheid state'

A Theranos scientist

Robert Kennedy Jr.'s presidential campaign attracts GOP

Twill hunts for pharma partner to market its depression app

Manchin plays down potential 3rd

leisure time

fashion

A looming test for neoantigen cancer vaccines

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Lack of darker skin in textbooks, journals harms patients of color

In age of alternative facts, a scholarly course on calling out crap

More hospitals are billing patients as online messages surge

United colonoscopy coverage change 'may cost lives,' doctors say

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Supreme Court strikes down use of affirmative action

Manchin plays down potential 3rd

Tori Bowie and the unacceptable rates of Black maternal death

Top private equity targets in 2023: cardiology, clinical trials, lasers

hotspot

Readout LOUD: Venture capital, Gilead, and more M&A

More hospitals are billing patients as online messages surge

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Johnson & Johnson sues to stop Medicare negotiation

Texas Medical Board asked to define abortion emergency exception

More hospitals are billing patients as online messages surge

hotspot

entertainment

entertainment

hotspot